Volume 272, Number 45, Issue of November 7, 1997
pp. 28501-28511
Cell Cycle-regulated Expression, Phosphorylation, and
Degradation of p55Cdc
A MAMMALIAN HOMOLOG OF CDC20/Fizzy/slp1*
(Received for publication, March 26, 1997, and in revised form, July 10, 1997)
Jasminder
Weinstein
From Amgen Inc., Thousand Oaks, California 91320
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
ABSTRACT
p55Cdc is a mammalian protein that shows high
homology to the cell cycle proteins Cdc20p of Saccharomyces
cerevisiae and the product of the Drosophila fizzy
(fzy) gene, both of which contain WD repeats and are
thought to be required for the metaphase-anaphase transition. The
fzy mutants exhibit a metaphase arrest phenotype, which is
accompanied by stabilization of cyclins A and B, leading to the
hypothesis that fzy function is required for cell
cycle-regulated ubiquitin-mediated proteolysis. p55Cdc expression was
initiated at the G1/S transition and steady state levels of
p55Cdc were highest at M and lowest in G1. Inhibition of
the 26 S proteasome prevented both mitotic exit and loss of p55Cdc at
the M/G1 transition, suggesting that p55Cdc degradation was
mediated by the cell cycle-regulated proteolytic pathway. Immune
complexes of p55Cdc obtained at different cell cycle stages showed a
variety of proteins with dramatic differences observed in the pattern
of associated proteins during the transition from G2 to M. Immunolocalization of p55Cdc demonstrated dynamic changes in p55Cdc
localization as the cells transit mitosis. p55Cdc appears to act as a
regulatory protein interacting with several other proteins, perhaps via
its seven WD repeats, at multiple points in the cell cycle.
INTRODUCTION
In eukaryotic cells, different complexes of kinases and their
associated activating or inhibitory proteins control progression through discrete steps of the cell cycle. The best understood complexes
known to play a central role in cell cycle progression are the cyclins
in association with their cyclin-dependent kinases (Cdks)1 (reviewed in Refs.
1-3). In addition to regulation by phosphorylation and association
with Cdk inhibitors, the cyclin-Cdk complexes are subject to a more
irrevocable form of regulation, i.e. the degradation of
cyclin via the cell cycle-regulated ubiquitin-mediated proteolytic
pathway (4-7). The work of a number of laboratories has recently
converged to identify three tetratricopeptide proteins, CDC16, CDC23,
and CDC27, as components of the E3 complex that becomes activated
during mitosis (8) and catalyzes the mitosis specific conjugation of
ubiquitin to B type cyclins in yeast (9) Xenopus (10), and
humans (11). These three proteins can form a large complex whose
function is required for the metaphase to anaphase transition (12).
Many of the genes encoding tetratricopeptide proteins have been
reported to functionally interact with members of the WD repeat family
(13, 14).
Recent investigations have demonstrated that other cell cycle-regulated
proteins undergo proteolysis at defined cell cycle stages, and that
proteins other than cyclins must be degraded to allow the metaphase to
anaphase transition (6, 7). Centromere protein (CENP)-E and CENP-F are mammalian kinetochore
localized proteins whose expression peaks at mitosis, exhibit dynamic
changes in their localization at different mitotic stages, and are
rapidly degraded after mitosis (15, 16). In Aspergillus
nidulans mitotic exit apparently requires the destruction of the
cell cycle-regulated NIMA protein kinase (17), and in
Drosophila the separation of sister chromatids has been
reported to require the product of the pimples gene, a
protein that is degraded after the metaphase-anaphase transition (18).
Most of these proteins do not have the cyclin destruction box motif,
which targets the A and B type cyclins for destruction (4).
We have (19) identified a protein, p55Cdc, which appears to be a
mammalian counterpart of products of the Saccharomyces cerevisiae
CDC20 (20), Drosophila fzy (21), and the newly described fission yeast slp1 (22) genes, due to the strong
homologies within their WD repeats (14). cdc20 mutants
arrest in mitosis at the nonpermissive temperature after the formation
of a complete short spindle and nuclear migration to the neck between
the mother cell and a large bud (23). It has been suggested that the
cdc20p is required for modulation of microtubule structure, either by altering the surface of microtubules or by promoting disassembly (20,
24). The fzy mutants have demonstrated that the failure to
degrade cyclins A and B, and the failure of sister chromatids to
separate, is due to a lack of functional Fizzy (Fzy) protein (21, 25).
Dawson et al. (21) have postulated that Fzy function is
required for cell cycle-regulated ubiquitin-mediated proteolysis. slp1 mutants are defective in chromosome separation and
recovery from DNA damage arrest (22). The high degree of homology
between p55Cdc, Fzy, Cdc20p, and slp1 protein, as well as their
essential role in cell cycle, has prompted the proposal that they are
orthologous members of a gene family within the highly degenerate WD
repeat superfamily (21, 22).
Mammalian p55Cdc exhibits several properties that are consistent with
its role in the cell cycle. p55Cdc, not expressed in differentiated or
quiescent cells, is readily detectable in dividing cells. p55Cdc
appears to be essential for cell division, since transfection of
antisense p55Cdc cDNA into Chinese hamster ovary cells results in
isolation of only those cells that exhibit a compensatory increase in
p55Cdc transcripts in the sense orientation (19). Immune complexes of
p55Cdc exhibited a protein kinase activity that was higher in actively
proliferating cells than in quiescent cells and fluctuated with the
cell cycle. Overexpression of p55Cdc in myeloid cells inhibited
granulocytic differentiation and accelerated apoptosis, suggesting that
p55Cdc regulation is critical for normal cell cycle control during
myeloid cell proliferation and differentiation (26).
This study was undertaken to examine the expression, phosphorylation,
degradation, and localization of p55Cdc at different stages of the
mammalian cell cycle. The mitotic Cdk, p34cdc2, was analyzed in
parallel and served as an additional control in the course of this
work. Pulse labeling experiments with 35S or
32P showed that both the biosynthesis and phosphorylation
of p55Cdc were low at G1 and peaked at G2, with
a significant drop in phosphorylation during the G2 to M
transition. Immunecomplexes, obtained from different cell cycle stages
and subcellular fractions, showed distinct p55Cdc-associated proteins.
A steady accumulation of p55Cdc during the course of the cell cycle
culminated in rapid loss at the M to G1 transition. This
loss could only be prevented by a 26 S proteasome inhibitor, suggesting
that p55Cdc may be another cell cycle protein to be degraded by the
cell cycle-regulated ubiquitin-mediated proteolytic pathway.
Localization of p55Cdc by indirect immunofluorescence displayed dynamic
changes during mitosis, from the centromeres at prometaphase, mitotic
spindle in metaphase, to the spindle equator in anaphase. These
observations indicate a role for p55Cdc in G2 and/or M.
MATERIALS AND METHODS
Cell Culture, Synchronization, Labeling, and Subcellular
Fractionation
HeLa and IMR-90 cells were grown in
-minimum
essential medium or minimum essential medium, respectively,
supplemented with 10% fetal bovine serum, glutamine, and nonessential
amino acids (Life Technologies, Inc.). HeLa cells were synchronized at
the beginning of S (G1/S) by the double
thymidine/aphidicolin block (27). S phase cells were harvested 4 h, G2 cells were harvested 8 h, and mitotic cells were
obtained by shake off 10-11 h following release from the aphidicolin
block. The remaining adherent monolayer was the late G2
population. To obtain a G1 population, the nonadherent pseudo-mitotic (G2/M) cells collected following 12-14 h of
nocodazole treatment (0.1 µg/ml) were washed and replated in media
without nocodazole. Approximately 60% of these cells had completed
mitosis 2 h later, and the daughter cells had adhered to the
plates by 3 h. At this stage, the nonadherent cells were rinsed
off. The cells were used for G1 analysis 4-8 h following
replating. To obtain cells at the M/G1 transition,
pseudo-mitotic cells were harvested 7 h after nocodazole
treatment. The washed cells were replated in media without drugs
(carrier dimethyl sulfoxide, Me2SO), or with media
containing the following additions: 50 µM
N-acetylleucylnorleucinal (LLnL), 50 µg/ml
(2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methyl-butane ethyl ester (E64d), 0.1 µg/ml staurosporine, or 5 µg/ml
dihydrocytochalasin B (DCB), (Sigma Chemical Co). Following a 2.5-h
incubation, the cells were analyzed for DNA content by flow cytometer
(DNA QC Particles kit, Becton Dickinson), and for p55Cdc, cyclin B, and p34cdc2 by Western analysis. An identical analysis was
performed on cells that had been treated for 15 h with 5 µg/ml
aphidicolin to obtain a population of cells accumulated in
G1 and S phase. IMR-90 cells were arrested in
G0 by growing the cells for 3 days in low serum (0.5%).
The quiescent cells were activated by addition of 20% serum to the
media, and the 35S-labeled cells were harvested at 4 h
intervals following activation. Cells were preincubated with
methionine- and cysteine-free media containing 5% dialyzed serum for
30 min, followed by 1 h in the same medium containing 100 µCi/ml
Tran35S-label (ICN Biomedicals Inc.). The media for the 0 time point contained only 0.5% dialyzed serum. 32P
labeling was done for 1 h after a 30-min incubation in
phosphate-deficient medium containing 5% dialyzed serum. The label
32Pi (ICN Biomedicals) was present at a
concentration of 0.5 mCi/ml.
Subcellular fractions were obtained by lysing the cells in a hypotonic
buffer (20 mM Hepes, pH 7.4, 5 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 0.1%
Nonidet P-40, 50 mM NaF, 100 mM
Na3VO4, 20 µg/ml aprotinin, 1 µg/ml
leupeptin, 10 µg/ml soybean trypsin inhibitor, and 50 µg/ml
phenylmethylsulfonyl fluoride) after a quick rinse in cold distilled
water. All protease inhibitors were purchased from Sigma. The cells
were left on ice for 30 min with intermittent swirling and then scraped
off the plates with a cell scraper. The nuclei were pelleted by a
1000 × g spin in a swinging bucket rotor for 10 min.
The supernatant was separated into S100 (cytosol) and P100
(particulate) fractions by spinning for 1 h at 100,000 × g. The nuclear and P100 pellets were resuspended in
radioimmunoprecipitation assay buffer, described previously (19).
Nonidet P-40 and NaCl were added to the S100 fraction to make its
composition closer to the other two fractions. The resuspended P100 and
nuclear fractions were spun for 30 min at 20,000 × g
to obtain a clarified lysate for immunoprecipitation experiments.
Preparation of a total cell lysate has been described previously (19).
All lysates were stored at
80 °C until needed.
Antibody Preparation and Immunoprecipitations
The
preparation of the antibody against a glutathione
S-transferase-p55Cdc fusion construct has been described
(19). Rabbit antibodies were generated against the carboxyl-terminal
end of p55Cdc (CKSSLIHQGIR), conjugated to keyhole limpet hemocyanin antigen. Antisera were affinity-purified by passage through a Sulfolink
(Pierce) column to which the peptide had been coupled. The column was
washed with 10 column volumes of PBS, and the affinity-purified antibodies were eluted with 0.1 M glycine, pH 2.8, into
tubes containing 1 M Tris, pH 8. The pH of the pooled
fractions was adjusted to neutral, and they were stored in aliquots at
80 °C. Protein concentrations were estimated with the
bicinchoninic acid reagent (Pierce). The protocol for
immunoprecipitations has been described (19). The concentration of
antibody was increased to 5 µg/100 µg of lysate for the glutathione
S-transferase-p55Cdc fusion protein antibody and to 15 µg/100 µg of lysate for the carboxyl-terminal peptide antibody. The
concentration of the control adsorbed antisera was always 5-10-fold
higher than that of the affinity-purified antibodies. Antibodies to
p34cdc2 (monoclonal antibody 17), cyclin A (BF683), cyclin E
(E-19), and goat polyclonal antibody against the carboxyl-terminal
peptide of human lamin B were purchased from Santa Cruz Biotechnology Inc. The monoclonal antibody to human cyclin B1 (GNS-1) was purchased from Pharmingen, and the monoclonal antibody to human lactate dehydrogenase was from Sigma. The band intensity was quantitated by
PhosphorImager analysis (Molecular Dynamics).
Immunoblots and Immunofluorescence
Total cell lysates were
prepared in 1.5 × SDS sample loading buffer (28) at a
concentration of 106 cells/0.15 ml. The subcellular
fractions were prepared exactly as described above, except that the
S100 fraction was concentrated so that normalization was by cell number
for all three fractions. The proteins were transferred to Hybond
nitrocellulose (Amersham Corp.) for 2 h at 80 mA with the
Pharmacia Multiphor II apparatus (Pharmacia Biotech Inc.). The
transferred proteins were visualized by the ECL detection system
(Amersham Corp). For indirect immunofluorescence experiments, an
asynchronous population of HeLa cells was fixed in
20 °C methanol,
2 mM EGTA for 10 min, blocked, and permeabilized for 7 min
in PBS containing 5% donkey serum and 0.1% Triton X-100 and rinsed
briefly in PBS, 0.1% BSA. The cells were incubated with 10 µg/ml
p55Cdc affinity-purified antibody and 1/50 dilution of
-tubulin
monoclonal antibody from Amersham Corp. or 50 µg/ml control adsorbed
antisera for 75 min. The slides were washed twice in PBS, 0.1% BSA and
blocked again with 5% donkey serum in PBS. Incubation with
fluorescence-labeled secondary antibodies (1/400 diluted Cy3 conjugated
to AffiniPure F(ab
)2 fragment donkey anti rabbit IgG, 1/100 diluted
FITC-conjugated AffiniPure F(ab
) fragment donkey anti rabbit IgG and
1/100 diluted FITC-conjugated AffiniPure F(ab
)2 fragment donkey anti
mouse IgG, Jackson ImmunoResearch Labs) was for 1 h. Slides were
washed twice in PBS, 0.1% BSA and once in PBS containing 2.5 µg/ml
Hoescht 33342 (Molecular Probes). The slides were rinsed in distilled
water and mounted in Vectashield (Vector Laboratories). Results were
observed under fluorescence with a Nikon Microphot-FXA equipped with a
Plan Apo 50× oil immersion lens (Nikon Inc). Cells at various mitotic
stages were photographed under identical conditions with the
appropriate filters. All experiments were performed reproducibly at
least twice.
RESULTS
p55Cdc Expression Is Initiated at the G1/S
Transition
Previous work demonstrated that p55Cdc expression was
readily detectable in a rapidly proliferating, but not quiescent
population of Rat1 fibroblasts (19). To identify the stage of the cell cycle at which p55Cdc expression is initiated, a normal diploid untransformed human fibroblast cell line was examined. IMR-90 cells
were arrested at G0 by serum starvation and induced to
enter the cell cycle by the addition of 20% serum to the medium.
IMR-90 cells enter S phase 16 h following serum stimulation and
show peak DNA synthesis at 24 h (29). At 4-h intervals following serum activation the cells were labeled with 35S and
immunoprecipitated with p55Cdc antibody or p34cdc2 antibody for
comparison. The results in Fig. 1 show
the appearance of p55Cdc 16 h following growth stimulation and a
barely detectable band at 12 h, coincidental with the biosynthesis
of p34cdc2. The p34cdc2 immunoprecipitates consistently
show a band of slightly higher mobility than p55Cdc, which could be due
to cyclin A. At 24 h both p55Cdc and p34cdc2 synthesis
were still increasing. Activation of p34cdc2 synthesis has been
shown to occur at the G1/S transition (30-32).
Fig. 1.
Initiation of p55Cdc synthesis after serum
activation. IMR-90 cells were 35S-labeled at 4-h
intervals following serum activation. 100 µg of total cell lysates
were immunoprecipitated with monoclonal antibody against
p34cdc2 (lanes 1, 3, 5,
7, 9, 11, and 13) or
affinity-purified p55Cdc antibody (lanes 2, 4,
6, 8, 10, 12, and
14). Lane 15 was immunoprecipitated with p55Cdc
adsorbed antiserum (control). Washed immunoprecipitates were analyzed
on 10% SDS-PAGE gels, followed by autoradiography.
[View Larger Version of this Image (44K GIF file)]
Half-life of p55Cdc
To determine the half-life of p55Cdc, an
asynchronous population of HeLa cells was labeled for 1 h with
35S and total cell lysates or subcellular fractions were
prepared after 0, 1, 2, 6, or 21 h of chase. Lanes 3,
5, 7, 9, and 12 in Fig.
2a show the amount of p55Cdc
at 0, 1, 2, 6, and 21 h following the labeling pulse.
PhosphorImager analysis revealed the half-life of p55Cdc to be 2 h, followed by a slower loss so that 35% of the label remained with
p55Cdc at 6 h (data not shown). p34cdc2 (Fig.
2a, lanes 2, 4, 6,
8, and 10) showed no significant loss of
radioactivity over the time course of the experiment but showed a
conversion to the slower mobility phosphorylated forms over time. This
result is generally in agreement with the reported long half-life of
18 h for this protein (31). PhosphorImager analysis of the
half-life of p55Cdc at different subcellular locations showed it to be
unique for each site. Comparison of p55Cdc detection of the S100
fraction (Fig. 2b, lanes 3, 5,
7, 9, and 12) showed the half-life in
this fraction to be approximately 1 h. The P100 fraction had a
half-life of 6 h (Fig. 2c), while the nuclear fraction still retained 70% of its radioactivity at this time (Fig.
2d). Apparently, the newly synthesized p55Cdc was rapidly
degraded or transferred from the cytosol to the cytoskeletal membranes and nucleus, where it had a longer half-life. Interestingly,
p34cdc2 showed a steadily increasing accumulation over time in
the P100 (Fig. 2c, lanes 2, 4,
6, 8, and 10) and nuclear (Fig.
2d, lanes 2, 4, 6,
8, and 10) fractions of the slower mobility
hyperphosphorylated form while the cytosol fraction (Fig.
2b) showed a steady loss of the high mobility form. This
would be consistent with the phosphorylation of p34cdc2 prior
to or immediately following nuclear entry.
Fig. 2.
Half-life of p55Cdc. Asynchronous HeLa
cells were 35S-pulse-labeled for 1 h and harvested at
0 (lanes 1-3), 1 (lanes 4 and 5), 2 (lanes 6 and 7), 6 (lanes 8 and
9), and 21 (lanes 10-12) h intervals to obtain
total cell lysates or subcellular fractions as described under
"Materials and Methods." Immunoprecipitates were collected from
100-µg samples with p55Cdc adsorbed antiserum (lanes 1 and
12), p34cdc2 monoclonal antibody (lanes
2, 4, 6, 8, and 10),
and affinity-purified p55Cdc antibody (lanes 3,
5, 7, 9, and 11). Washed
immunoprecipitaes from total cell lysates (a), S100
fractions (b), P100 fractions (c), and nuclear
fractions (d) were analyzed on 10% SDS-PAGE gels followed
by autoradiography.
[View Larger Version of this Image (52K GIF file)]
Expression, Phosphorylation, and Subcellular Distribution of p55Cdc
at Different Stages of the Cell Cycle
To analyze the cell
cycle-regulated expression, distribution and phosphorylation status of
p55Cdc, HeLa cells were synchronized and labeled at various stages of
the cell cycle (Fig. 3a). At indicated times, the cells were solubilized and the lysates
immunoprecipitated. Since p55Cdc is known to be associated with protein
kinase(s) activity, which fluctuates with the cell cycle (19) and
partitions to different subcellular
locations,2 it would be of
interest to observe p55Cdc immune complexes from the cytosol (S100),
particulate (P100), and nuclear fractions. Biosynthesis of p55Cdc in
HeLa cells was detectable in G1 and increased steadily
through the cell cycle to peak at G2 (Fig. 3, b
and c). The regulation of p55Cdc biosynthesis was similar to
that of p34cdc2, being very low at G1 and peaking
at G2. The p55Cdc immunoprecipitates showed the presence of
a 100-kDa protein in the P100 and nuclear fractions through the entire
cell cycle. The p34cdc2 immunoprecipitates showed a faint band
that appeared to comigrate with p55Cdc and could be due to cyclin A
and/or B. A 10-fold increase in the rate of p34cdc2 synthesis
has been observed as HeLa cells progress from G1 to G2 (33). Although the bulk of newly synthesized
p34cdc2 was found in the S100 fraction, p55Cdc had the highest
relative concentration in the P100 fraction (Fig. 3c) and
this pattern did not change with the cell cycle. As expected, the
nuclear p34cdc2 in the G2 samples was primarily the
slower mobility (inactive) form, while that in the S100 and P100
fraction of mitotic cells (Fig. 3b) was of the faster
mobility (active) form.
Fig. 3.
p55Cdc synthesis at different stages of the
cell cycle. HeLa cells were synchronized and
35S-labeled at various cell cycle stages as described under
"Materials and Methods." The DNA content obtained by flow cytometry
for a typical experiment is shown in a.
, 2 and 4 N DNA content. Immunoprecipitates (b) from S100
(S), P100 (P), and nuclear (N)
fractions were collected from a 100-µg sample with p34cdc2
monoclonal antibody (lanes 4) or p55Cdc affinity-purified
antibodies (lanes 2) or p55Cdc adsorbed antiserum
(lanes 1). Washed immunoprecipitates were analyzed on 10%
SDS-PAGE gels. The gels from b were subjected to
PhosphorImager analysis, and the data were graphed
(c).
[View Larger Version of this Image (39K GIF file)]
The results of labeling HeLa cells with 32P for 1 h at
different stages of the cell cycle are shown in Fig.
4. The late G2 cells represent the adherent monolayer after the mitotic cells have been
harvested by repeated pipetting. This population also has cells that
have already exited mitosis and entered G1. p55Cdc phosphorylation is undetectable in any of the fractions obtained from a
G1 population of cells, followed by progressive increase in
phosphorylation of p55Cdc as the cells proceed from G1 to
G2. The p55Cdc immunoprecipitates from P100 fractions (Fig.
4b, lanes 2 and 3) contain a
unidentified band of 35 kDa that co-migrates with the slower mobility
form of p34cdc2, and is undetectable in the mitotic P100
fraction. The S100 fractions (Fig. 4a, lanes 2 and 3) showed a diffuse band at longer exposures (data not
shown), which could represent different phosphorylated forms of p55Cdc.
Immune complexes obtained from the nuclear fraction with antibody
against glutathione S-transferase-p55Cdc fusion protein
(Fig. 4c, lane 2) also showed a slower migrating
band around 58 kDa that was not detected by the p55Cdc COOH-terminal antibody (Fig. 4c, lane 3). Since the nuclear
membrane has disintegrated in the mitotic cells, only the S100 and P100
fractions were obtained. The mitotic S100 fraction showed a unique
profile of p55Cdc-associated phosphorylated proteins in the immune
complex, including the appearance of proteins of 72 and 140 kDa. The
same profile was obtained by two different antibodies to p55Cdc (Fig.
4a, lanes 2 and 3). The rate of
p34cdc2 phosphorylation in the various subcellular fractions
from different stages in the cell cycle (Fig. 4, a,
b, and c, lane 4) paralleled that of
p55Cdc, although unlike p55Cdc, phosphorylated p34cdc2 was
detectable during G1. Enhancement in the rate of
p34cdc2 phosphorylation at G2 has been observed
previously (34).
Fig. 4.
Distribution of 32P-labeled
p55Cdc at different stages of the cell cycle. HeLa cells were
synchronized and 32P-labeled at various cell cycle stages
as described under "Materials and Methods." Immunoprecipitates for
panels a (S100, cytosol fraction), b (P100,
particulate fraction), and c (nuclear fraction) were collected with p55Cdc adsorbed antiserum (lane 1),
affinity-purified p55Cdc antibodies (lane 2), p55Cdc
COOH-terminal antibodies (lane 3), and p34cdc2
monoclonal antibody (lane 4). Washed immunoprecipitates were analyzed on 10% SDS-PAGE gels followed by autoradiography.
[View Larger Version of this Image (52K GIF file)]
The data obtained in Fig. 4 were subjected to PhosphorImager analysis,
and the results are shown in Fig. 5.
Except for the late G2 population, both proteins exhibit
the highest concentration of phosphorylated protein in the P100
fraction. This is noteworthy since 35S labeling detected
most p34cdc2 in the cytosol fraction and similar results were
obtained for the distribution of p34cdc2 in the various
subcellular fractions (Fig. 6,
lanes 1-3), although longer exposure showed detectable low
mobility form of p34cdc2 in the membrane fraction (data not
shown). Thus, the p34cdc2 associated with cell membranes must
be in a highly phosphorylated state. This is consistent with the report
that myt1, the inhibitory kinase that phosphorylates p34cdc2 on
both threonine 14 and tyrosine 15, is a membrane-associated kinase (35,
36). In this context, it is interesting that human cyclin B2 has been
localized primarily to the Golgi apparatus (37). The phosphorylation
rate of both p55Cdc (Fig. 5a) and p34cdc2 (Fig.
5b) peak at G2 and show a dramatic
dephosphorylation at M. However, although p55Cdc showed an overall
dephosphorylation in transition from G2 to M, the S100
fraction showed an increase in net phosphorylation of p55Cdc during
mitosis.
Fig. 5.
Distribution of phosphorylated p55Cdc during
the cell cycle. The SDS-PAGE gels shown in Fig. 4
(a-c) were subjected to PhosphorImager analysis and the
results were graphed. a and b show the results
obtained for p55Cdc and for p34cdc2, respectively. Solid
bars, S100 (cytosol); open bars, P100 (particulate membranes); hatched bars, nuclear fraction.
[View Larger Version of this Image (25K GIF file)]
Fig. 6.
Steady state levels of p55Cdc. a,
total cell lysates from synchronized or asynchronous (A)
HeLa cells were prepared for SDS-PAGE as described under "Materials
and Methods." A G2 population was used to prepare
subcellular fractions (S100, lane 1; P100, lane
2; nuclear, lane 3). Subcellular fractions obtained from 0.66 × 106 cells and total lysates from
0.33 × 106 cells were loaded for Western blot
analysis. The nitrocellulose blots were developed with
affinity-purified p55Cdc antibody; p34cdc2 antibody; cyclin A
(BF683) antibody and cyclin E (C-19) antibodies. b,
characterization of affinity-purified p55Cdc antibody. Total cell
lysates from 0.07 and 0.20 × 106 HeLa cells were
loaded on lanes 1 and 2, respectively, for
immunoblot analysis with affinity-purified p55Cdc antibody.
c, characterization of subcellular fractions. Total cell
lysate from 0.17 × 106 cells (lane 1) and
subcellular fractions (S100, lane 2; P100, lane
3; nuclear, lane 4) from 0.33 × 106
cells were loaded. Appropriate sections of the blot were probed with
three different antibodies: antibody to human lactate dehydrogenase as
a cytosolic marker, antibody to
-tubulin as a cytosoilc and cytoskeletal membrane protein marker, and antibody to lamin B as a
nuclear protein marker.
[View Larger Version of this Image (33K GIF file)]
Steady State Levels of p55Cdc
To estimate the steady state
levels of p55Cdc at different points in the cell cycle, synchronized
HeLa cells were harvested and lysed in SDS-PAGE sample buffer. The
amount loaded per well was normalized by cell number and not protein
content and gave approximately equal amount of protein in lanes
4-10 (Fig. 6a).To obtain the G1
population, rounded cells were collected following a nocodazole block,
plated, and the adherent monolayer was harvested 4 and 8 h later.
Western blots were performed with antibodies against p55Cdc,
p34cdc2, cyclin E, and cyclin A (Fig. 6a). The
results demonstrated that p55Cdc was present at a much lower
concentration in G1 compared with the other stages of the
cell cycle. The concentration of p55Cdc increased as the cells
progressed through the cell cycle and peaked at M. This was followed by
a dramatic loss of p55Cdc as the cells started a new cycle at
G1. In contrast, cyclin A and E do not show such a dramatic
fluctuation. Cyclin A peaked at G1/S and was maintained at
a high level through G2. This result is in agreement with
that of Dulic et al. (38), but does not completely agree
with that of Pines and Hunter (39), who observed a continuous increase
in cyclin A levels up to 8 h following release from an aphidicolin
block. However, their samples were normalized for protein content and
not cell number. The cyclin E levels peaked at G1/S and
declined thereafter as had been observed (38). Subcellular fractionation of a G2 population (fractions normalized by
cell number) showed that both cyclin A and E are present in the nucleus as had been observed previously by immunofluorescence (40, 41). The
same analysis of p55Cdc distribution revealed it to be present in all
three fractions, even in the P100 sample where far less total protein
was loaded. It was most abundant in the nuclear fraction.
p34cdc2 showed a fairly even distribution throughout the cell
cycle except for the lower amounts in the G1 cells. Welch
and Wang (31) have concluded that, after mitosis and through
G1, the p34cdc2 is old dephosphorylated protein
from the previous cycle.
Characterization of the affinity-purified p55Cdc antibody used in this
study is shown in Fig. 6b. Increasing amount of total HeLa
cell lysate was loaded in lanes 1 and 2 and the
blot developed with the p55Cdc fusion protein antibody preparation. A
predominant band at 55 kDa and a weaker band at about 33 kDa were
detected. The 33-kDa band could be due to degraded p55Cdc as suggested
previously (19). A duplicate blot probed with p55Cdc adsorbed antiserum did not show any reaction (data not shown). The results demonstrate the
specificity of the antibody and indicate that the proteins detected in
the p55Cdc immune complexes (Figs. 3 and 4) are not due to
contaminating antibodies. The quality of the subcellular fractions
obtained by the simple process of hypotonic cell lysis followed by
differential centrifugation is shown in Fig. 6c. Total cell
lysate was loaded in lane 1 and S100, P100, and nuclear
fractions in lanes 2-4, respectively. The glycolytic enzyme
lactate dehydrogenase served as a marker for the cytosol fraction
(S100),
-tubulin was a marker for both cytosol and cytoskeletal
membrane fraction (P100), and the nuclear membrane protein lamin B was
a marker for the nuclear fraction. As expected, the lactate
dehdrogenase antibody detected the enzyme in the S100 fraction, the
-tubulin antibody detected this protein primarily in the S100 and
P100 fractions, and the lamin B antibody demonstrated that this protein is present only in the nuclear fraction. These results verify the
purity of the subcellular fractions.
p55Cdc Is Degraded at the M to G1 Transition
This
analysis was performed to understand the mechanism of p55Cdc loss that
had been observed by Western analysis of HeLa cells at various cell
cycle stages. Cells that had been arrested at G2/M or
G1 and S were released to continue their cell cycle progression either in the absence or presence of a variety of drugs.
The cell-permeable cysteine protease inhibitor LLnL has been shown to
inhibit cyclin B degradation and induce cell cycle arrest in Chinese
hamster ovary and HeLa cells (42) and has been used as a specific 26 S
proteasome inhibitor in many studies (43-46). The lipid-soluble
cell-permeable calpain 1 and 11 and lysosomal protease inhibitor E64d
is a useful control since it does not appear to inhibit the 26 S
proteasome and does not show any cell cycle perturbations (44, 47).
Staurosporine is a nonspecific protein kinase inhibitor, which can
inhibit certain Cdk-cyclin complexes at very low concentrations (48)
and has been used to inhibit the p34cdc2 kinase following
release from a nocodazole arrest (49). This treatment leads to a
reduction in histone phosphorylation, chromosome decondensation, and
nuclear membrane reformation, suggesting a premature exit from mitosis
and resetting of the cell cycle clock to a G1 state in the
absence of cytokinesis (49). Dihydrocytochalasin B is a drug that
interferes with actin assembly and cell cleavage (50). A large
proportion of cells treated with DCB following release from a
nocodazole arrest failed to complete cleavage yet entered interphase
(G1) by the criteria of decondensed chromatin and reformed
nuclear envelopes (50). HeLa cells that had been arrested in mitosis by
nocodazole (Fig. 7, a and
b, 1-6) or in G1 and S by a single
aphidicolin treatment (Fig. 7, a and b,
7-12) were allowed to reenter the cell cycle in the
presence or absence of these drugs. After 2.5 h, all the cells
were harvested and analyzed for the levels of p55Cdc, cyclin B, or
p34cdc2 by Western analysis (Fig. 7a) or for DNA
content to obtain cell cycle status (Fig. 7b). Although most
of the cells treated by Me2SO alone (carrier) had exited
into G1 at this time (Fig. 7b, 2),
those treated by LLnL and staurosporine showed complete arrest at 4 N. The DCB treatment resulted in a partial block and even the E64d treatment showed some inhibition of mitotic exit. Results from
the immunoblot revealed that the only drug able to prevent the
proteolysis of p55Cdc and cyclin B was the 26 S proteasome inhibitor
LLnL, although E64d did show some inhibition of cyclin B degradation.
Overall, the pattern of p55Cdc loss was very similar to that of cyclin
B, which is known to be destroyed by the cell cycle-regulated
ubiquitin-mediated 26 S proteasome pathway during anaphase/telophase
(4, 7). Neither p55Cdc nor cyclin B showed readily detectable
ubiquitinated bands moving with lower mobility on the SDS-PAGE gels in
the LLnL-treated samples. Other investigators have found the need to
overexpress a cyclin (46) or overexpress a cyclin along with an
engineered ubiquitin construct to enable the detection of
polyubiquitinated species (47). As expected, the levels of
p34cdc2 were unaffected by any of the drug treatments and the
enzyme stayed in its high mobility dephosphorylated form (Fig.
7a, 1-6). Release from aphidicolin arrest caused
a surge of DNA synthesis, as seen by the peak between the 2 and 4 N peaks under all experimental conditions except one (Fig.
7b, 8-10 and 12). The only drug that showed a detectable inhibition of DNA synthesis was staurosporine, probably by virtue of its ability to inhibit Cdk2 the catalytic component of both Cdk2-cyclin E and Cdk2-cyclin A complexes (48). The
cells released from aphidicolin arrest showed no detectable p55Cdc
accumulation with any of the inhibitors including LLnL when compared
with cells treated with carrier alone (Fig. 7a, 7-12), demonstrating that the cell cycle-regulated p55Cdc
degradation is active at the M to G1 transition and has
been turned off by the time the cells are in late G1 and S
phase of the cell cycle.
Fig. 7.
Loss of p55Cdc at the M to G1
transition. HeLa cells were synchronized with nocodazole
(1-6) or aphidicolin (7-12) and samples
prepared for immunoblots (a) or DNA content (b)
as described under "Materials and Methods." The blot was probed
with antibodies to p55Cdc, cyclin B, and p34cdc2. The
dotted line shows the profile obtained from a normal
asynchronous HeLa cell population.
, 2 and 4 N DNA
content.
[View Larger Version of this Image (31K GIF file)]
Immunolocalization of p55Cdc in Mitotic HeLa Cells
Indirect
immunofluorescence was performed to visualize the cellular location of
p55Cdc during mitotic stages. The colocalization of p55Cdc and
-tubulin at progressive mitotic stages is shown in Fig.
8. The immunofluorescence of p55Cdc in
mitotic cells was more intense than that in interphase cells and, in
early mitotic stages, appeared to interfere with the ability of the
-tubulin monoclonal antibody to stain the mitotic spindle (Fig.
8a). The intense speckled nuclear staining of prophase (Fig.
8a) was reduced dramatically at prometaphase (Fig.
8a), at which point it appeared to be localized to the
centromere region of the chromosome rosette formation where juxtaposed
centromeres can appear as a single fluorescent ring (51). The
kinetochores of Ptk1 cells show p55Cdc localization during early
mitotic stages.3 Chromosomes
within the rosette are oriented with their arms projecting outward from
the centromere ring, which forms at the rim of the hub of the
chromosome rosette (51). At this stage, p55Cdc appears to be localized
to the centromere ring and cell cortex. As the cells enter metaphase
(Fig. 8b), p55Cdc localized to the mitotic spindle and the
cytosol (in both a normal bipolar and an abnormal tripolar spindle) but
was now excluded from the region occupied by the condensed chromosomes.
At this stage, the interference with
-tubulin staining has lessened
sufficiently to allow the detection of microtubules by the
-tubulin
antibody. Some spindle pole association could still be detected during
early anaphase (Fig. 8c), along with p55Cdc staining as a
bisecting strip at the spindle equator, which continued as
intracellular bridge staining when the cells were in late
anaphase and telophase (Fig. 8, d and e). The
intracellular bridge staining did not continue as midbody staining in
cytokinesis (Fig. 8f) in contrast to the intense
-tubulin
staining in this region, although a small dot of p55Cdc staining
persisted at the site of maximum cleavage furrow constriction. p55Cdc
fluorescence was at its highest intensity during prophase and metaphase
and declined steadily thereafter, so that by cytokinesis (Fig.
8f) it was down to the levels detected in interphase.
Fig. 8.
Colocalizationof p55Cdc and
-tubulin in
mitotic cells. An asynchronous HeLa cell population was subjected
to indirect immunofluorescence as described under "Materials and
Methods" and cells representing progressive mitotic stages were
photographed: a (prophase and prometaphase), b
(metaphase), c (anaphase), d (late anaphase),
e (telophase), and f (cytokinesis). The primary antibodies were affinity-purified p55Cdc antibodies (10 µg/ml, a-f), 1/50 diluted
-tubulin monoclonal antibody
(a-f), and p55Cdc adsorbed antiserum (50 µg/ml,
g).
[View Larger Version of this Image (108K GIF file)]
The intensity of p55Cdc staining was always higher when no attempt was
made to co-localize with
-tubulin. To clearly visualize the polar
spindle staining during anaphase (Fig.
9a) and telophase (Fig.
9b), indirect immunofluorescence was performed on HeLa cells with the affinity-purified p55Cdc antibody alone. No
immunofluorescence was detectable with the control p55Cdc adsorbed
antiserum (data not shown). The results clearly demonstrate the
presence of p55Cdc at the spindle poles during these mitotic stages.
Although p55Cdc was localized to the spindle poles, p55Cdc staining was
never detected exclusively at the centrosome with the staining protocol used in this study.
Fig. 9.
p55Cdc localization at the spindle
poles. An asynchronous HeLa cell population was subjected to
indirect immunofluorescence as described under "Materials and
Methods." The primary antibody was affinity-purified p55Cdc antibody
(10 µg/ml) and the secondary antibody was FITC-conjugated donkey anti
mouse IgG. Cells representing anaphase (a) and telophase
(b) were photographed under identical conditions.
[View Larger Version of this Image (100K GIF file)]
DISCUSSION
Mammalian p55Cdc is a cell cycle protein that is expressed in an
actively cycling population of cells (19) and first appears, following
activation of a quiescent population of cells, during late
G1 (Fig. 1). This expression pattern is coincidental with that of p34cdc2, the synthesis of which is initiated at the
G1/S transition (30, 31), and the results of Furukawa
et al. (32) suggest that expression of p34cdc2
following exposure of T cells to phytohemagglutinin is coincident with
the G1 to S transition as part of an orderly sequence of events that occurs at this stage. These results imply that the induction of p55Cdc synthesis at the G1/S transition could
be part of such a sequence. The potential role of p55Cdc at this transition and in S phase is under investigation.
p55Cdc immunoprecipitates are associated with multiple protein kinases,
with the myelin basic protein phosphorylating activity seen
predominantly in the S100 fraction and the
-casein protein kinase
activity segregating with the nucleus2 (19). Therefore, it
was decided to examine subcellular fractions in an attempt to identify
potential protein kinase bands for future analysis. p55Cdc has a short
half-life of 2 h in an asynchronous population of HeLa cells.
Pulse-labeled p55Cdc and p34cdc2 show dynamic changes in their
subcellular locations with time. The short-lived p55Cdc rapidly leaves
the cytosol to accumulate in the membrane and nuclear fractions while
the stable p34cdc2 shows a much slower exit from the cytosol
(Fig. 2, b-d). Fig. 3b shows a 100-kDa protein
in association with p55Cdc in the P100 and nuclear fractions through
the course of the cell cycle. It is interesting that this association
is no longer observed in a pseudo-mitotic population of cells collected
following nocodazole treatment.2 It is also evident that
p55Cdc associates with different proteins at different subcellular
locations during the cell cycle, a dramatic change in the pattern of
associated proteins occurring in the transition from G2 to
M (Fig. 4). The results of Figs. 3, 4, 5 demonstrate that both the
biosynthesis and phosphorylation of p55Cdc are cell cycle-regulated,
being low at G1 and progressively increasing with the
course of the cell cycle to peak at G2. The p55Cdc
phosphorylation/dephosphorylation cycle appears to peak prior to the
p55Cdc protein accumulation/degradation cycle. Future experiments will
determine if this is coincidental or of functional significance.
The identification of the Drosophila fzy gene as a homolog
of p55Cdc and CDC20 may provide some clues toward a
mechanism for p55Cdc function. p55Cdc and Fzy have 50% overall
identity due to the significant homology that extends beyond the WD
repeats (21). The observation that the metaphase arrest phenotype
caused by fzy mutations is associated with failure to
degrade both mitotic cyclins A and B has led to the suggestion that
fzy function is required for cell cycle-regulated
proteolysis (21). Sigrist et al. (25) have also proposed
that exit from mitosis is regulated by Fzy-mediated sequential
destruction of cyclins A, B, and B3 and that it is involved in sister
chromosome separation and segregation. Although there is no direct
evidence to implicate the Fzy homologs cdc20p and p55Cdc in a cell
cycle-regulated proteolytic pathway, the immunolocalization of p55Cdc
during mitosis (Fig. 8) is similar to that reported for Fzy (21) in
that the mitotic cytosol is intensely stained by antibodies against
both proteins, while these proteins are excluded from the region
occupied by the condensed chromosomes. However, Fzy staining was not
detected at the centromeres during prometaphase, the spindle during
metaphase, or the spindle equator and poles during anaphase and
telophase as p55Cdc was (Figs. 8 and 9). These are all locations where
a protein involved in microtubule dynamics might be predicted to occur.
The reason for this difference in localization of these homologous
proteins might be due to species or technical differences.
Ubiquitin-mediated proteolysis is known to be induced by
phosphorylation (7, 46, 47, 52), and reversible phosphorylation is
implicated in controlling the activity of cyclosome-associated, cyclin-ubiquitin ligase (53). p55Cdc is associated with a protein kinase activity through most of the cell cycle (19). However, the loss
of an intact nucleus following nocodazole treatment or entry into
metaphase2 results in the loss of detectable
-casein
kinase activity in the p55Cdc immune complex (19), although high levels
of p55Cdc are detectable by Western blot (Fig. 6) and indirect
immunofluorescence (Fig. 8) during mitosis. Could the release of a
protein kinase or modulation of its substrate specificity by the
p55Cdc-kinase(s) complex allow it to phosphorylate a specific mitotic
substrate hitherto inaccessible? Furthermore, p55Cdc itself is
phosphorylated and this phosphorylation is regulated by the cell cycle,
being undetectable at G1 and peaking at G2, a
pattern that corresponds to that of the phosphorylation of
p34cdc2 (Figs. 4 and 5). p55Cdc has five potential
phosphorylation sites among amino acid residues 41-109, which conform
to the (S/T)PX(R/K) consensus for Cdk phosphorylation (54,
55). The transition from G2 to M is accompanied by a net
dephosphorylation of p55Cdc, yet the mitotic cytosol shows an increase
in phosphorylated p55Cdc and a unique pattern of p55Cdc-associated
phosphorylated proteins. It is intriguing that p55Cdc immune complexes
obtained from the mitotic cytosol of 32P-labeled cells
showed phosphorylated proteins of 140 and 72 kDa that were undetectable
in the same fraction obtained from interphase cells (Fig.
4a). The onset of mitosis is known to coincide with the
appearance of many phosphorylated proteins in the cytosol (56).
Identification of the proteins associated with p55Cdc may increase our
understanding of the cell cycle-regulated, ubiquitin-mediated proteolytic pathway.
The dramatically lower levels of p55Cdc observed at G1
suggested a precise cell cycle-regulated loss of this protein (Fig. 6).
A decrease in the half-life of p55Cdc during mitosis from that observed
in an asynchronous population (2 h), in conjunction with the very low
levels of p55Cdc synthesis observed during G1 (Fig. 3),
could account for the observed loss of this protein in transition from
M to G1. Steady state levels of mitotic B cyclins peak at M
and show a similar precipitous drop at mitosis (40). The degradation of
the B type cyclins is triggered at the metaphase-anaphase transition
and has been shown recently to continue through G1 in
S. cerevisiae and mammalian cells (43, 57). The kinetics of
p55Cdc accumulation and degradation also bear an interesting similarity
to those observed for CENP-E, a putative kinetochore kinesin-related
motor protein (15); CENP-F, a nuclear matrix protein that assembles
onto kinetochores at late G2 and is rapidly degraded after
mitosis (16); and the mammalian Polo-like kinase Plk1, implicated in
mitotic spindle function (58, 59). p55Cdc escapes complete proteolysis
through the course of mitosis but is largely lost by cytokinesis (Fig.
8). Drugs that inhibit cytokinesis by a variety of mechanisms were
unable to prevent the degradation of p55Cdc or cyclin B (Fig. 7). The
only drug capable of inhibiting p55Cdc and cyclin B proteolysis was the
26 S proteasome inhibitor LLnL, suggesting that not only could p55Cdc
be an essential regulatory component of this complex (21, 25) perhaps
by interacting with the anaphase promoting complex (7), but also be
ultimately degraded by it. This significant observation lends further
support to the hypothesis that cell cycle-regulated proteolysis plays a
major role in regulating mitotic exit and resetting the cell cycle
machinery to a G1 state.
The dynamic changes observed in p55Cdc localization at progressive
mitotic stages (Fig. 8) imply a role for this protein at more than one
mitotic transition. The increase in p55Cdc staining intensity as the
cells enter prophase appears to coincide with nuclear envelope
breakdown. Recent studies have suggested that the abrupt reorganization
of microtubules at nuclear envelope breakdown is the result of a
decrease in microtubule polymer level and increase in microtubule
dynamics during prophase (60). The microtubule polymer levels recover
as the chromosomes attach to the microtubules during prometaphase and
metaphase since the captured kinetochore microtubules are protected
from the rapid turnover of other microtubules (60, 61). The
three-dimensional analysis and ultrastructural design of mitotic
spindles from the cdc20 mutant of S. cerevisiae
showed that the cdc20p may be involved in cell cycle processes that
promote microtubule disassembly (24).
The centromere has been proposed to be the hub of chromosomal
activities (62) and is stained by p55Cdc when the chromosomes are
transiently arrayed in a chromosome rosette formation (Fig. 8a). During metaphase, p55Cdc staining could be detected at
the mitotic spindle and cytosol and at the spindle equator in anaphase. The interference of
-tubulin immunofluorescence by p55Cdc antibodies during these early mitotic stages implies either a direct or indirect association of p55Cdc with
-tubulin or very close spatial proximity of these two antigens during these transitions. Moreover, both the
S. cerevisiae and Drosophila homologs of p55Cdc
have been implicated in modulating microtubule behavior. The
loss-of-function mutations in cdc20 and fzy leads
to a mitotic arrest phenotype that is accompanied by an excess
accumulation of tubulin in the spindle microtubules (20, 21, 24). These
properties would be consistent with a role for p55Cdc as a component of
the spindle assembly and metaphase to anaphase transition checkpoints
(63, 64).
p55Cdc has been shown to be localized to the centromeres
(prometaphase), spindle poles (metaphase, anaphase and telophase), and
spindle equator (anaphase and telophase), where it might participate in
regulating the cross-linking of interdigitating, antiparallel, interpolar microtubules (65). This would be consistent with the
observation that cdc20 mutant spindles showed significantly more cross-bridges between spindle microtubules than were seen in the
wild type (24). The kinetic changes in p55Cdc localization during
mitosis are reminiscent of the BimC family of kinesin-related motor
proteins that have been proposed to function in spindle pole
(centrosome) separation, spindle assembly, chromosome movement and to
control microtubule dynamics within the spindle (66-68), and the
chromosomal passenger proteins that include the inner centromere proteins (INCENPs). These proteins
are proposed to associate with chromosomes, particularly the
centromeres in prophase, as a means for positioning themselves at the
metaphase plate and the spindle midzone during anaphase (69). The TD-60
antigen has also been shown to accumulate at the equatorial position of the mitotic spindle in anaphase and persist at the intracellular bridge
during telophase (50, 69, 70). The telophase disc (TD) has been
postulated to be a mitotic organelle that is templated by the mitotic
spindle, maintains contact with the cortex, and forms at the proper
place and time (equator of a cell in anaphase) to play a role in
cytokinesis (70). In rat kidney cells, cleavage activity correlated
with the distribution of midzone microtubule bundles and TD-60 protein
rather than the position of spindle poles or polar microtubules (71).
Recent studies that measured the traction forces of cytokinesis in
adherent cultured fibroblasts lend support to a model in which cell
division occurs through increased contractility at the spindle equator
and subsequent deepening of the cleavage furrow (72). Localization of
p55Cdc to the centromeres at prophase could facilitate its subsequent accumulation at the spindle equator during anaphase and telophase where
it might participate as a telophase disc component. It is intriguing
that p55Cdc staining persists as a dot marking the site of maximum
cleavage furrow constriction during cytokinesis (Fig. 8f)
while the TD-60 antigen and several other
centromere/kinetochore-associated antigens concentrated at the spindle
midbody at this stage (70, 73). In this context, it is interesting to
note that immunolocalization of Plk1 in HeLa cells following metaphase
also showed intense staining at the spindle equator and close to the
midbody at the site of cleavage furrow during cytokinesis (59).
Apparently, p55Cdc is shed from the midbody microtubule bundles as the
daughter cells separate by migration and severing of the intercellular connection. Thus, p55Cdc appears at the right place and time to play a
role in mitotic transitions.
Several WD proteins form multiprotein complexes, the
-subunit of
heterotrimeric G proteins being the paradigm, and in many cases these
protein-protein interactions are known to be mediated via the WD
repeats (14). New insight into the crystal structure of G-protein
heterotrimer and the G
dimer revealed that G
is shaped like a seven-bladed propeller (seven WD
repeats) with a central shaft tunnel connecting the two faces (see Ref. 74, and references therein). The
-propeller has been proposed to
represent the probable architecture of all WD repeat containing domains. The conserved core of the WD repeats form the scaffold to
expose their more variable linker regions on the surface of each
propeller blade. One could speculate that the seven WD repeats of
p55Cdc could form a similar structure, thus providing an ideal dynamic
molecular scaffold for a variety of protein-protein interactions at
different subcellular locations and stages of the cell cycle. However,
an understanding of the mechanism of action of this interesting protein
must await the identification of its interacting proteins.
FOOTNOTES
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Amgen Inc., 14-1-B,
1840 DeHavilland Dr., Thousand Oaks, CA 91320. Tel.: 805-447-4097; Fax:
805-447-1982; E-mail: jweinste{at}amgen.com.
1
The abbreviations used are: Cdk,
cyclin-dependent kinase; CENP, centromere protein; LLnL,
N-acetylleucylnorleucinal; E64d, (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methyl-butane
ethyl ester; DCB, dihydrocytochalasin B; S100, 100,000 × g supernatant; P100, 100,000 × g pellet;
Plk, Polo-like kinase; PAGE, polyacrylamide gel electrophoresis; BSA,
bovine serum albumin; PBS, phosphate-buffered saline; TD, telophase
disc; FITC, fluorescein isothiocyanate.
2
J. Weinstein, unpublished observations.
3
G. Gorbsky, personal communication.
ACKNOWLEDGEMENTS
I gratefully acknowledge the Amgen Boulder
peptide synthesis group and Marynette Rihanek for production of the
p55Cdc COOH-terminal antibody and David Lyons for support and helpful
discussions. I thank Linda Baum, Kathy Sakamoto, Pam Hunt, and Steve
Coats for critical reading of the manuscript and Karen Rosenblum for help in its preparation. I also thank Martha Hokom for help with the
fluorescence-activated cell sorting analysis and Vicki Gottmer for
graphics.
REFERENCES
-
Morgan, D. O.
(1995)
Nature
374,
131-134
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sherr, C. J.
(1994)
Cell
79,
551-555
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sherr, C. J., and Roberts, J. M.
(1995)
Genes Dev.
9,
1149-1163
[Free Full Text]
-
Glotzer, M., Murray, A. W., and Kirschner, M. W.
(1991)
Nature
349,
132-137
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hershko, A., Ganoth, D., Pehrson, J., Palazzo, R. E., and Cohen, L. H.
(1991)
J. Biol. Chem.
266,
16376-16379
[Abstract/Free Full Text]
-
Holloway, S. L., Glotzer, M., King, R. W., and Murray, A. W.
(1993)
Cell
73,
1393-1402
[CrossRef][Medline]
[Order article via Infotrieve]
-
King, R. W., Deshaies, R. J., Peters, J. M., and Kirschner, M. W.
(1996)
Science
274,
1652-1659
[Abstract/Free Full Text]
-
Sudakin, V., Ganoth, D., Dahan, A., Heller, H., Hershko, J., Luca, F. C., Ruderman, J. V., and Hershko, A.
(1995)
Mol. Biol. Cell
6,
185-198
[Abstract]
-
Irniger, S., Piatti, S., Michaelis, C., and Nasmyth, K.
(1995)
Cell
81,
269-278
[CrossRef][Medline]
[Order article via Infotrieve]
-
King, R. W., Peters, J. M., Tugendreich, S., Rolfe, M., Hieter, P., and Kirschner, M. W.
(1995)
Cell
81,
279-288
[CrossRef][Medline]
[Order article via Infotrieve]
-
Tugendreich, S., Tomkiel, J., Earnshaw, W., and Hieter, P.
(1995)
Cell
81,
261-268
[CrossRef][Medline]
[Order article via Infotrieve]
-
Lamb, J. R., Michaud, W. A., Sikorski, R. S., and Hieter, P. A.
(1994)
EMBO J.
13,
4321-4328
[Medline]
[Order article via Infotrieve]
-
Goebl, M., and Yanagida, M.
(1991)
Trends Biochem. Sci.
16,
173-177
[CrossRef][Medline]
[Order article via Infotrieve]
-
Neer, E. J., Schmidt, C. J., Nambudripad, R., and Smith, T. F.
(1994)
Nature
371,
297-300
[CrossRef][Medline]
[Order article via Infotrieve]
-
Brown, K. D., Coulson, R. M. R., Yen, T. J., and Cleveland, D. W.
(1994)
J. Cell Biol.
125,
1303-1312
[Abstract/Free Full Text]
-
Liao, H., Winkfien, R. J., Mack, G., Rattner, J. B., and Yen, T. J.
(1995)
J. Cell Biol.
130,
507-518
[Abstract/Free Full Text]
-
Pu, R. T., and Osmani, S. A.
(1995)
EMBO J.
14,
995-1003
[Medline]
[Order article via Infotrieve]
-
Stratmann, R., and Lehner, C. F.
(1996)
Cell
84,
25-35
[CrossRef][Medline]
[Order article via Infotrieve]
-
Weinstein, J., Jacobsen, F. W., Hsu-Chen, J., Wu, T., and Baum, L. G.
(1994)
Mol. Cell. Biol.
14,
3350-3363
[Abstract/Free Full Text]
-
Sethi, N., Monteagudo, M. C., Koshland, D., Hogan, E., and Burke, D. J.
(1991)
Mol. Cell. Biol.
11,
5592-5602
[Abstract/Free Full Text]
-
Dawson, I. A., Roth, S., and Artavanis-Tsakonas, S.
(1995)
J. Cell Biol.
129,
725-737
[Abstract/Free Full Text]
-
Matsumoto, T.
(1997)
Mol. Cell. Biol.
17,
742-750
[Abstract]
-
Byers, B., and Goetsch, L.
(1974)
Cold Spring Harbor Symp. Quant. Biol.
38,
123-131
[Medline]
[Order article via Infotrieve]
-
O'Toole, E. T., Mastronarde, D. N., Giddings, T. M., Winey, M., Burke, D. J., and McIntosh, J. R.
(1997)
Mol. Biol. Cell
8,
1-11
[Abstract]
-
Sigrist, S., Jacobs, H., Stratmann, R., and Lehner, C. F.
(1995)
EMBO J.
14,
4827-4838
[Medline]
[Order article via Infotrieve]
-
Kao, C. T., Lin, M., O'Shea-Greenfield, A., Weinstein, J., and Sakamoto, K. M.
(1996)
Oncogene
13,
1221-1229
[Medline]
[Order article via Infotrieve]
-
Heintz, N., Sive, H. L., and Roeder, R. G.
(1983)
Mol. Cell. Biol.
3,
539-550
[Abstract/Free Full Text]
-
Laemmli, U. K.
(1970)
Nature
227,
680-685
[CrossRef][Medline]
[Order article via Infotrieve]
-
Pagano, M., Pepperkok, R., Lukas, J., Baldin, V., Ansorge, W., Bartek, J., and Draetta, G.
(1993)
J. Cell Biol.
121,
101-111
[Abstract/Free Full Text]
-
Lee, M. G., Norbury, C. J., Spurr, N. K, and Nurse, P.
(1988)
Nature
333,
676-679
[CrossRef][Medline]
[Order article via Infotrieve]
-
Welch, P. J., and Wang, J. Y. J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
3093-3097
[Abstract/Free Full Text]
-
Furukawa, Y., Piwnica-Worms, H., Ernst, T. J., Kanakura, Y., and Griffin, J. D.
(1990)
Science
250,
805-808
[Abstract/Free Full Text]
-
McGowan, C. H., Russel, P., and Reed, S. I.
(1990)
Mol. Cell. Biol.
10,
3847-3851
[Abstract/Free Full Text]
-
Draetta, G., and Beach, D.
(1988)
Cell
54,
17-26
[CrossRef][Medline]
[Order article via Infotrieve]
-
Mueller, P. R., Coleman, T. R., Kumagai, A., and Dunphy, W. G.
(1995)
Science
270,
86-90
[Abstract/Free Full Text]
-
Liu, F., Stanton, J. J., Wu, Z., and Piwnica-Worms, H.
(1997)
Mol. Cell Biol.
17,
571-583
[Abstract]
-
Jackman, M., Firth, M., and Pines, J.
(1995)
EMBO J.
14,
1646-1654
[Medline]
[Order article via Infotrieve]
-
Dulic, V., Lees, E., and Reed, S. I.
(1992)
Science
257,
1958-1961
[Abstract/Free Full Text]
-
Pines, J., and Hunter, T.
(1990)
Nature
346,
760-763
[CrossRef][Medline]
[Order article via Infotrieve]
-
Pines, J., and Hunter, T.
(1991)
J. Cell Biol.
115,
1-17
[Abstract/Free Full Text]
-
Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., and Pagano, M.
(1995)
Mol. Cell. Biol.
15,
2612-2624
[Abstract]
-
Sherwood, S. W., Kung, A. L., Roitelman, J., Simon, R. D., and Schimke, R. T.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
3353-3357
[Abstract/Free Full Text]
-
Brandies, M., and Hunt, T
(1996)
EMBO J.
15,
5280-5289
[Medline]
[Order article via Infotrieve]
-
Pagano, M., Tam, S. W., Theodorads, A. M., Beer-Romero, P., Sal, G. D., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M.
(1995)
Science
269,
682-685
[Abstract/Free Full Text]
-
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A. L.
(1994)
Cell
78,
761-771
[CrossRef][Medline]
[Order article via Infotrieve]
-
Won, K.-A., and Reed, S. I.
(1996)
EMBO J.
15,
4182-4193
[Medline]
[Order article via Infotrieve]
-
Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M., and Roberts, J. M.
(1996)
Genes Dev.
10,
1979-1990
[Abstract/Free Full Text]
-
Gadbois, D. M., Hamaguchi, J. R., Swank, R. A., and Bradbury, E. M.
(1992)
Biochem. Biophys. Res. Commun.
184,
80-85
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hall, L. L., Th'ng, J. P. H, Guo, X. W., Teplitz, R. L., and Bradbury, E. M.
(1996)
Cancer Res.
56,
3551-3559
[Abstract/Free Full Text]
-
Martineau, S. N., Andreassen, P. R., and Margolis, R. L.
(1995)
J. Cell Biol.
131,
191-205
[Abstract/Free Full Text]
-
Nagele, R., Freeman, T., McMorrow, L., and Lee, H.
(1995)
Science
270,
1831-1835
[Abstract/Free Full Text]
-
Deshaies, R. J.
(1995)
Trends Cell Biol.
5,
428-434
-
Lahav-Baratz, S., Sudakin, V., Ruderman, J. V., and Hershko, A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9303-9307
[Abstract/Free Full Text]
-
Draetta, G.
(1990)
Trends Biochem. Sci.
15,
378-383
[CrossRef][Medline]
[Order article via Infotrieve]
-
Holmes, J. K., and Solomon, M. J.
(1996)
J. Biol. Chem.
271,
25240-25246
[Abstract/Free Full Text]
-
Davis, F. M., Tsao, T. Y., Fowler, S. K., and Rao, P. N.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
2926-2930
[Abstract/Free Full Text]
-
Amon, A., Irniger, S., and Nasmyth, K.
(1994)
Cell
77,
1037-1050
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hamanaka, R., Smith, M. R., O'Connor, P. M., Maloid, S., Mihalic, K., Spivak, J. L., Longo, D. L., and Ferris, D. K.
(1995)
J. Biol. Chem.
270,
21086-21091
[Abstract/Free Full Text]
-
Golsteyn, R. M., Mundt, K. E., Fry, A. M., and Nigg, E. A.
(1995)
J. Cell. Biol.
129,
1617-1628
[Abstract/Free Full Text]
-
Zhai, Y., Kronebusch, P. J., Simon, P. M., and Borisy, G. G.
(1996)
J. Cell Biol.
135,
201-214
[Abstract/Free Full Text]
-
Kirshner, M., and Mitchison, T.
(1986)
Cell
45,
329-342
[CrossRef][Medline]
[Order ar